Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ: AMGN). Under the provisions of…
Source: Celimmune licenses anti-IL-15 monoclonal antibody from Amgen
Monday, March 2, 2015
Celimmune licenses anti-IL-15 monoclonal antibody from Amgen
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment